Neogenomics Stock

Neogenomics Buyback Yield

Buyback Yield of Neogenomics (NEO) as of Aug 15, 2026.

Buyback Yield

0.00

Last updated:

Buyback Yield of Neogenomics is 2026 0.00 . Buyback Yield of Neogenomics was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

On Eulerpool you can find the complete historical development of Buyback Yield Neogenomics since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's Neogenomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Neogenomics

All Key Metrics — Neogenomics